Influenza

Safety and Efficacy: IV Zanamivir vs Oral Oseltamivir in Severe Influenza

By

Cindy Lampner

Intravenous zanamivir is as safe and effective as oral oseltamivir when used in patients with severe influenza.

FDA to Review Baloxavir for Pediatric Use, Postexposure Prophylaxis of Influenza

By

Diana Ernst, RPh

Baloxavir inhibits the endonuclease activity of the polymerase acidic protein resulting in inhibition of influenza virus replication.

Neuraminidase Inhibitor Treatment for Influenza B-Related Pneumonia

By

Zahra Masoud

Early neuraminidase inhibitor therapy may result in better outcomes in patients hospitalized with influenza B-related pneumonia.

Adjuvanted FLU-v Vaccine Immunogenic in Healthy Adults

Results of early research support further development of a synthetic universal influenza vaccine.

Evaluation of Trivalent vs Quadrivalent Inactivated Vaccine for Influenza B

By

Sweta Gupta

Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.

Antibiotic and Antiviral Combination to Treat Influenza

By

Zahra Masoud

Compared with patients prescribed only an antiviral, patients who are prescribed both an antiviral and antibiotic have a lower risk for 3-day respiratory hospitalization.

Fluad Quadrivalent Influenza Vaccine Approved for Older Adults

By

Diana Ernst, RPh

The FDA has approved Fluad Quadrivalent (influenza vaccine, adjuvanted; Seqirus) for active immunization in patients 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine.

Double-Dose Influenza Vaccine Doses May Not Benefit Pregnant Women With HIV

By

Pulmonology Advisor Contributing Writer

A double-dose of inactivated influenza vaccine may not increase the immunogenicity of the vaccine among pregnant women with HIV.

FDA Approves Novel Influenza A (H5N1) Vaccine

By

Diana Ernst, RPh

The FDA has approved the influenza A H5N1 vaccine for active immunization in patients 6 months of age and older with increased risk of exposure.